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Introduction
Mevalonate kinase deficiency (MKD) is a rare autosomal
recessive disorder causing 1 of 2 phenotypes, hyper-
immunoglobulin D syndrome and mevalonic aciduria,
presenting with recurrent fever episodes, often starting in
infancy, and sometimes evoked by stress or vaccinations.
This autoinflammatory disease is caused by mutations
encoding the mevalonate kinase (MVK) gene and is classi-
fied in the group of periodic fever syndromes. HIDS is
characterized by recurrent fever attacks of 3-7 days that
begin in infancy and recur every 4-6 weeks. The febrile
period is accompanied by lymphadenopathy, arthralgia,
abdominal pain, diarrhea, aphthous ulcers, and varying
degree of skin involvement. The course and severity of the
disease may be quite different. There is no effective or
proven therapy for HIDS.
Objectives
We aim to determine the clinical and genetic characteris-
tics together with the underlying MVK genotypes in single
center during a period of 2 years.
Methods
A retrospective review of medical records for patients
referred for HIDS over 2 years. We obtain 40 patients
(22 female, 18 male) and 25 healthy controls.
Results
The median age of first attack was 33 months (range 2-62
months). The median age of diagnosis was 60 months.
The most common symptoms of high fever accompanied
respectively: lymphadenopathy (n=27), abdominal pain
(n=26), arthralgia (n=20), diarrhea (n=15), aphthous sto-
matitis (n=13), vomiting (n=12) and maculopapuler rash
(n=6) were determined. Amyloidosis was found in a
patient (0.3%). The mean serum IgD level was 129±92
mg/dl, it was be normal in 43% of patients.
We found mutations in 75% of patients (n=30) in exon
3 and 11 (c155G>A; c1129G>A) in MVK gene. We
applied colchicine therapy in 40% of patients while inter-
mittent steroid therapy 20% of patients. Empiric colchicine
(40%) and glucocorticosteroids (20%) controlled flares in
majority of patients with HIDS. Three patients had also
tonsillectomy. We used biologic therapy in 3 patients
(canacinumab (n=2), anakinra (n=1)).
Conclusion
In conclusion, HIDS is characterized with early onset an
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